Hae Won Kim1,2, Jae Seung Kim3, Minyoung Oh4, Jungsu S Oh4, Sang Joo Lee4, Seung Jun Oh4, Sun Ju Chung5, Chong Sik Lee5. 1. Department of Nuclear Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea. 2. Department of Nuclear Medicine, School of Medicine, Keimyung University, 56 Dalseong-ro, Jung-gu, Daegu, 700-712, Republic of Korea. 3. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea. jaeskim@amc.seoul.kr. 4. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea. 5. Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Abstract
PURPOSE: The aim of this study was to evaluate whether striatal dopamine transporter (DAT) loss as measured by (18)F-fluorinated-N-3-fluoropropyl-2-b-carboxymethoxy-3-b-(4-iodophenyl) nortropane ([(18)F]FP-CIT) PET differs according to the metabolic subtype of multiple system atrophy (MSA) as assessed by [(18)F]FDG PET. METHODS: This retrospective study included 50 patients with clinically diagnosed MSA who underwent [(18)F]FP-CIT and [(18)F]FDG brain PET scans. The PET images were analysed using 12 striatal subregional volume-of-interest templates (bilateral ventral striatum, anterior caudate, posterior caudate, anterior putamen, posterior putamen, and ventral putamen). The patients were classified into three metabolic subtypes according to the [(18)F]FDG PET findings: MSA-Pm (striatal hypometabolism only), MSA-mixedm (both striatal and cerebellar hypometabolism), and MSA-Cm (cerebellar hypometabolism only). The subregional glucose metabolic ratio (MRgluc), subregional DAT binding ratio (BRDAT), and intersubregional ratio (ISRDAT; defined as the BRDAT ratio of one striatal subregion to that of another striatal subregion) were compared according to metabolic subtype. RESULTS: Of the 50 patients, 13 presented with MSA-Pm, 16 presented with MSA-mixedm, and 21 presented with MSA-Cm. The BRDAT of all striatal subregions in the MSA-Pm and MSA-mixedm groups were significantly lower than those in the MSA-Cm group. The posterior putamen/anterior putamen ISRDAT and anterior putamen/ventral striatum ISRDAT in the MSA-Pm and MSA-mixedm groups were significantly lower than those in the MSA-Cm group. CONCLUSION: Patients with MSA-Pm and MSA-mixedm showed more severe DAT loss in the striatum than patients with MSA-Cm. Patients with MSA-Cm had more diffuse DAT loss than patients with MSA-Pm and MSA-mixedm.
PURPOSE: The aim of this study was to evaluate whether striatal dopamine transporter (DAT) loss as measured by (18)F-fluorinated-N-3-fluoropropyl-2-b-carboxymethoxy-3-b-(4-iodophenyl) nortropane ([(18)F]FP-CIT) PET differs according to the metabolic subtype of multiple system atrophy (MSA) as assessed by [(18)F]FDG PET. METHODS: This retrospective study included 50 patients with clinically diagnosed MSA who underwent [(18)F]FP-CIT and [(18)F]FDG brain PET scans. The PET images were analysed using 12 striatal subregional volume-of-interest templates (bilateral ventral striatum, anterior caudate, posterior caudate, anterior putamen, posterior putamen, and ventral putamen). The patients were classified into three metabolic subtypes according to the [(18)F]FDG PET findings: MSA-Pm (striatal hypometabolism only), MSA-mixedm (both striatal and cerebellar hypometabolism), and MSA-Cm (cerebellar hypometabolism only). The subregional glucose metabolic ratio (MRgluc), subregional DAT binding ratio (BRDAT), and intersubregional ratio (ISRDAT; defined as the BRDAT ratio of one striatal subregion to that of another striatal subregion) were compared according to metabolic subtype. RESULTS: Of the 50 patients, 13 presented with MSA-Pm, 16 presented with MSA-mixedm, and 21 presented with MSA-Cm. The BRDAT of all striatal subregions in the MSA-Pm and MSA-mixedm groups were significantly lower than those in the MSA-Cm group. The posterior putamen/anterior putamen ISRDAT and anterior putamen/ventral striatum ISRDAT in the MSA-Pm and MSA-mixedm groups were significantly lower than those in the MSA-Cm group. CONCLUSION:Patients with MSA-Pm and MSA-mixedm showed more severe DAT loss in the striatum than patients with MSA-Cm. Patients with MSA-Cm had more diffuse DAT loss than patients with MSA-Pm and MSA-mixedm.
Entities:
Keywords:
Dopamine transporter; Multiple system atrophy; [18F]FP-CIT
Authors: Esteban Muñoz; Alex Iranzo; Sebastian Rauek; Francisco Lomeña; Judith Gallego; Doménec Ros; Joan Santamaría; Eduardo Tolosa Journal: J Neurol Date: 2011-06-03 Impact factor: 4.849
Authors: O Mawlawi; D Martinez; M Slifstein; A Broft; R Chatterjee; D R Hwang; Y Huang; N Simpson; K Ngo; R Van Heertum; M Laruelle Journal: J Cereb Blood Flow Metab Date: 2001-09 Impact factor: 6.200
Authors: I Litvan; C G Goetz; J Jankovic; G K Wenning; V Booth; J J Bartko; A McKee; K Jellinger; E C Lai; J P Brandel; M Verny; K R Chaudhuri; R K Pearce; Y Agid Journal: Arch Neurol Date: 1997-08
Authors: S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet Journal: Neurology Date: 2008-08-26 Impact factor: 9.910
Authors: Michael Nocker; Klaus Seppi; Sylvia Boesch; Eveline Donnemiller; Irene Virgolini; Gregor K Wenning; Werner Poewe; Christoph Scherfler Journal: Mov Disord Clin Pract Date: 2016-11-02
Authors: Minyoung Oh; Narae Lee; Chanwoo Kim; Hye Joo Son; Changhwan Sung; Seung Jun Oh; Sang Ju Lee; Sun Ju Chung; Chong Sik Lee; Jae Seung Kim Journal: Sci Rep Date: 2021-07-22 Impact factor: 4.379
Authors: Changhwan Sung; Jai Hyuen Lee; Jungsu S Oh; Minyoung Oh; Sang Ju Lee; Seung Jun Oh; Sun Ju Chung; Chong Sik Lee; Jae Seung Kim Journal: Nucl Med Mol Imaging Date: 2017-04-06